of March 31, 2018, and December 31, 2017, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii)
of SEC Regulation S-K.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
have been no material changes in our qualitative and quantitative market risk since the disclosures in our Annual Report on Form
10-K, as amended, for the year ended December 31, 2017, except as follows:
Method Accounting for Asterias and OncoCyte shares at fair value
account for our Asterias and OncoCyte shares using the equity method of accounting fair value option. The value of those shares
is subject to changes in the stock price. Asterias and OncoCyte common stock trade on the NYSE
American under the ticker symbols “AST” and “OCX”, respectively. As of March 31, 2018, the 52-week
high/low closing stock price per share range for Asterias was $4.05 to $1.45, and for OncoCyte was $7.55 to $1.25.
Item 4. Controls and Procedures
of Disclosure Controls and Procedures
is management’s responsibility to establish and maintain adequate internal control over all financial reporting pursuant
to Rule 13a-15 under the Securities Exchange Act of 1934 (“Exchange Act”). Our management, including our principal
executive officers and our principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls
and procedures as of the end of the period covered by this report. Following this review and evaluation, management collectively
determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us
in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods
specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer
and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
in Internal Control over Financial Reporting
were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report
on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial